AzTrials
AzTrials

Polycystic Ovary SyndromePOLYNCT01150539

Effects of Exercise for Overweight Women With Polycystic Ovary Syndrome

A study testing 16-week exercise training program in people with Polycystic Ovary Syndrome and Obesity, run by Pennington Biomedical Research Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with Polycystic ovary syndrome (PCOS). Read more about this study

Who is it for?
Ages 18 to 30 years, women only
Conditions the study is for
Polycystic Ovary Syndrome, Obesity
What is being tested?
16-week exercise training program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
1 siteUnited States
Study dates
Jan 2007to Jun 2007
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 30 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Women between the ages of 18-30, inclusive.
  • BMI greater than or equal to 25.
  • Sedentary lifestyle - not currently exercising more than 60 minutes per week.
  • A medical diagnosis of polycystic ovary syndrome. The diagnosis will be compared with the most recent international criteria1. Together with irregular menses (fewer than 6 cycles per year), participants must also have at least one of the following characteristics;
  • presence of polycystic ovaries on transvaginal ultrasound, >10 cysts, 2-8 mm in diameter (ultrasound will not be done in this study however; ultrasound reports will be used if available) and/or
  • clinical manifestations (hirsutism) examined by the PI at the screening visit or biochemical evidence (elevated testosterone or free androgen index) of hyperandrogenism, determined by fasting blood sample collected during the screening visit.
  • Women enrolling for the non-PCOS control group are required to have regular menstrual cycles (one cycle per month).

Who cannot join

  • Individuals with a history of cardiovascular disease or an elevated blood pressure above 160/90 mmHg.
  • Individuals with a history of Diabetes (Type 1 or Type 2).
  • Individuals with a history of Kidney, Liver or Heart disease.
  • Individuals with untreated thyroid disease.
  • Individuals who smoke.
  • Individuals who exercise more than 60 minutes per week.
Show all 13Show fewer
  • Individuals who use medications including contraceptives (medications used to treat thyroid disease are permitted).
  • Individuals with alcoholism or other substance abuse.
  • Individuals who are pregnant or lactating (breast feeding).
  • Individuals who become pregnant throughout the study will be excluded.
  • Individuals who are trying to become pregnant.
  • Control subjects will be excluded if they have irregular menses (fewer than 1 cycle per month).
  • Unable to complete approximately 60 minutes of medium intensity exercise per day (5 days per week) at the Pennington Health and Fitness Center (PCOS Group Only).

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana, 70808

Other trials in United States

About this study

Official title: Effects of Physical Activity on Insulin Resistance and Adiposity in Polycystic Ovary Syndrome "Poly"

The effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with Polycystic ovary syndrome (PCOS).

Read the detailed description

Young, overweight/obese women with PCOS along with age and BMI-matched healthy controls without PCOS will be enrolled in this study. Participants will have assessments of body composition (by DEXA), visceral and ectopic fat (by MR), ovarian parameters (follicle size and number, by MRI) insulin sensitivity (by euglycemic hyperinsulinemic clamp), interstitial lipolysis (by microdialysis), whole body lipolysis and glycolysis (by stable isotopes), aerobic fitness (by VO2max test) and a fat biopsy performed across two clinic visits (1 outpatient visit, and 1 overnight stay). Participants in the control group will undergo these assessments once only, whereas participants in the PCOS Group will have these assessments twice, once at baseline and once following a 16 week supervised aerobic exercise program. Throughout the exercise program body weight will be measured weekly and menstrual cycle frequency will be documented on a calendar. Additionally, vital signs, weight, waist and hip circumferences will be measured and a fasting blood sample collected every 4 weeks.

Being tested
16-week exercise training program, Control Group without PCOS
Medical subject headings
Polycystic Ovary Syndrome, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 16-week exercise training programOther

    The primary objective of the study is to investigate the effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with PCOS.

  • Control Group without PCOSOther

    A group of overweight/obese women without PCOS will be enrolled as a control group and will be studied only once at baseline to allow for comparisons between the two study populations.

Study groups in NCT01150539
Study groupRoleWhat they receive
Overweight/obese women with PCOSExperimental10 overweight/obese women with polycystic ovary syndrome
Receives: Other: 16-week exercise training program; Other: Control Group without PCOS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Insulin sensitivity as measured by the euglycemic hyperinsulinemic clamp

    16-weeks of aerobic exercise training on: peripheral insulin sensitivity (euglycemic-hyperinsulinemic clamp) and catecholamines (microdialysis) during a euglycemic-hyperinsulinemic clamp.

    Measured: Baseline and 16-weeks

Secondary outcomes (1)
  1. Change in adiposity (whole body measurement by dual x-ray absorptiometry and visceral measured by magnetic resonance imaging)

    16-weeks of aerobic exercise training on total and free testosterone concentraions and frequency of menstruation, Body lipolysis, and visceral fat.

    Measured: Baseline and 16-weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2010 (estimated)
  2. Study startJan 2007
  3. Primary completionMay 2007
  4. Study completionJun 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01150539
Sponsor's protocol ID
PBRC 26038
Acronym
POLY
Status last verified
Aug 2021
First submitted
22 Jun 2010
Last updated
25 Aug 2021
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing 16-week exercise training program in people with Polycystic Ovary Syndrome and Obesity, run by Pennington Biomedical Research Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Insulin sensitivity as measured by the euglycemic hyperinsulinemic clamp (time frame: Baseline and 16-weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in